# A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers

> **NCT05563961** · NA · UNKNOWN · sponsor: **Sinew Pharma Inc.** · enrollment: 48 (estimated)

## Conditions studied

- Hepatitis
- Pharmacology

## Interventions

- **DRUG:** Panadol®
- **DRUG:** SafeTynadol®

## Key facts

- **NCT ID:** NCT05563961
- **Lead sponsor:** Sinew Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-28
- **Primary completion:** 2024-06
- **Final completion:** 2024-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05563961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05563961, "A Partial Randomized, Single-blind or Open-label, Dose-escalation With Multiple-dose Design Study to Evaluate the Pharmacokinetics of Acetaminophen and Its Toxic Metabolites With Panadol® and SafeTynadol® in Healthy Volunteers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05563961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*